Hla-e molecule induction on the surface of tumor cells protects them from cytotoxic lymphocytes

Voprosy Onkologii

Volumn 55, Issue 2, 2009, Pages 224-229

  Berezhnoy, A Ye ^a   Chernysheva, A D ^a   Zakeeva, I P ^a   Danilova, A B ^b   Danilov, A O ^b   Moiseyenko, V M ^b   Geraghty, D ^c   Gnouchev, N V ^a   Georgiyev, G P ^a   Kibardin, A V ^a   Larin, S S ^a,d  

^a RUSSIAN ACADEMY OF SCIENCES   (Russian Federation)

^b N N PETROV RESEARCH INSTITUTE OF ONCOLOGY   (Russian Federation)

^c Fred Hutchinson Cancer Research Center   (United States)

^d PIROGOV RUSSIAN NATIONAL RESEARCH MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

HLA E ANTIGEN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CELL PROTECTION; CELL SURFACE; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; HUMAN; IMMUNOLOGICAL TOLERANCE; MELANOMA CELL; MOLECULAR MECHANICS; PROTEIN EXPRESSION; PROTEIN INDUCTION; TREATMENT RESPONSE; TUMOR CELL;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA ANTIGENS; HUMANS; IMMUNOBLOTTING; INTERFERON-GAMMA; MELANOMA; POLYMERASE CHAIN REACTION; T-LYMPHOCYTES, CYTOTOXIC;

EID: 67049095492     PISSN: 05073758     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Russian source
2. Borrego R, Ulbrecht M., Weiss E. et al. Recognition of human histocompatibility leukocyte antigen (HLA)-E complexed with HLA class I signal sequence-derived peptides by CD94/NKG2 confers protection from natural killer cell-mediated lysis // J. Exp. Med.-1998.-Vol. 187.-P. 813-818.
3. Cerboni C, Mousavi-Jazi M., Wakiguchi H. et al. Synergistic effect of IFN-gamma and human cytomegalovirus protein UL40 in the HLA-E-dependent protection from NK cell-mediated cytotoxicity // Europ. J. Immunol.-2001.-Vol. 31.-P. 2926-2935.
4. Hodi E, Mihm M., Soiffer R. et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients // Proc. Natl. Acad. Sci. (USA).-2003.-Vol. 100.-P. 4712-4717.
5. Coudert B.P., Arnould L, Moreau L. et al. Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trial // Ann. Oncol.-2006.-Vol. 17.-P. 409-414.
6. Lee N., Goodlett D., Ishitani A. et al. HLA-E surface expression depends on binding of TAP-dependent peptides derived from certain HLA class I signal sequences//J. Immunol.-1988.-Vol. 160.-P. 4951-4960.
7. Lee N., Llano M., Carretero M. et al. HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A // Proc. Natl. Acad. Sci. (USA).-1998.-Vol.95.-P. 5199-5204.
8. Leibson P.J. The regulation of lymphocyte activation by inhibitory receptors // Curr. Opin. Immunol.-2004.-Vol. 16.-P. 328-336.
9. Malmberg K., Levitsky V., Norell H. et al. IFN-gamma protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism // J. Clin. Invest.-2002.-Vol. 110.-P. 1515-1523.
10. Michaelsson J., Teixeira de Matos C, Achour A. et al. A signal peptide derived from hsp60 binds HLA-E and interferes with CD94/NKG2A recognition // J. Exp. Med.-2002.-Vol. 196.-P. 1403-1414.
11. Miller J., Weber D., Ibegbu C. et al. Analysis of HLA-E peptide-binding specificity and contact residues in bound peptide required for recognition by CD94/NKG2 // J. Immunol.-2003.-Vol. 3.-P. 1369-1375.
12. Rosenberg S.A., Yang J.C., Restifo N.P. Cancer immunotherapy: moving beyond current vaccines // Natl. Med.-2004.-Vol. 10.-P. 909-915.
13. Sambrook J., Fritsch E., Maniatis T. Molecular Cloning: A Laboratory Manual (2 nd edn).-Cold Spring Harbor Laboratory Press: Cold Spring Harbor, 1989.-P. 1847-1875.